RUA Life Sciences Triples Revenues and Nears Profitability After Abiss Acquisition

RUA Life Sciences ( (GB:RUA) ) just unveiled an update.

RUA Life Sciences has delivered a transformational 18‑month period to 30 September 2025, more than tripling revenue to £6.7m compared with the prior 12‑month period, while sharply reducing its loss before tax to £0.2m and turning EBITDA positive at £0.4m. The purchase of French CDMO Abiss has strengthened its contract manufacturing platform, contributed a £0.9m bargain‑purchase gain and helped lift CDMO revenues to £5.8m, while biomaterials income grew 23% on a like‑for‑like basis to £914,000 despite currency headwinds; combined with cost-cutting, reduced R&D spend and a refocus from R&D-heavy development to commercially driven growth, the group has achieved its 2023 strategic goals of doubling revenue, lowering cash burn and moving toward sustainable profitability ahead of schedule. With year‑end cash of £3.25m, improving cash generation from operations and an expanding pipeline of development and manufacturing contracts, management expects current activity levels to continue, positioning the company to broaden services to existing clients, win new customers and further commercialise its vascular and structural heart intellectual property in a highly regulated, long‑cycle but high‑margin medical device market.

The most recent analyst rating on (GB:RUA) stock is a Hold with a £16.00 price target. To see the full list of analyst forecasts on RUA Life Sciences stock, see the GB:RUA Stock Forecast page.

Spark’s Take on GB:RUA Stock

According to Spark, TipRanks’ AI Analyst, GB:RUA is a Neutral.

The score is primarily driven by solid top-line growth and a conservative balance sheet, but it is held back by weak profitability and negative operating cash flow. Technicals are supportive due to an established uptrend, yet the very high P/E meaningfully detracts from the overall rating.

To see Spark’s full report on GB:RUA stock, click here.

More about RUA Life Sciences

RUA Life Sciences is a UK-based medical device-focused contract development and manufacturing organisation (CDMO) specialising in implantable textile components and devices, underpinned by its proprietary long-term implantable biostable polymer Elast-Eon. Through subsidiaries including RUA Biomaterials and its recently acquired French unit Abiss, the group targets international growth by licensing its polymer technology, supplying medical device components, and partnering to monetise its portfolio of polymer, composite material and manufacturing process intellectual property, with the stated aim of becoming a long‑term trusted partner to large medical device companies and maximising shareholder value via profitable growth or selective disposals.

Average Trading Volume: 213,039

Technical Sentiment Signal: Hold

Current Market Cap: £9.62M

See more data about RUA stock on TipRanks’ Stock Analysis page.